Buying Amlin: a full entry into the Lloyd’s market (2015)

A caution that will not settle things with one big deal

The meaning of the Amlin acquisition cannot be captured as simply a success or a failure. The roughly ¥642 billion deal — among the largest overseas M&A ever done by the group — went through a long struggle after closing and ended in the sale of the entire shareholding; on its own terms, it did not reach plan. Yet MS&AD did not respond by retreating from overseas markets. It narrowed the Lloyd’s business down under the MS Amlin name, retrained its underwriting discipline, and kept it. This was management that took the picture drawn in a single large acquisition and spent years redrawing it.

The North American bolt-on strategy that followed is an extension of the same caution. Rather than settling the matter at a stroke with another deal in the hundreds of billions of yen, it stacked small and mid-sized investments, firming up its footing while looking for the next move — a manner that echoes the temperament of its Mitsui and Sumitomo predecessors. Ambition enough to push into high-return markets abroad, and realism enough to admit failure and rebuild. The dozen-odd years of Amlin can be looked back on as an overseas strategy that held both at once.